Edonerpic

DB05938InvestigationalSmall molecule

Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

Mechanism: T-817MA has neuroprotective properties. Toyama Chemical has demonstrated that T-817MA prevents neurodegeneration induced by Amyloid-b protein. Accumulation of Amyloid-b protein is considered to be central to the pathogenesis of Alzheimer's disease. The neuroprotective properties of T-817MA were also observed in a mutant tau induced Alzheimer's disease model. Besides these neuroprotective properties, T-817MA also promotes neurite outgrowth.
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease.Curator reviewed
Formula / weight: C₁₆H₂₁NO₂S · 291.41 g/mol (avg)
Code names: J2.972.359A · T-817

Resolves to

Compound

Structure

InChIKeyHQNACSFBDBYLJP-UHFFFAOYSA-NSMILESOC1CN(CCCOCCC2=CC3=C(SC=C3)C=C2)C1

Targets

What you can answer from here — as of September 12, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Edonerpic, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.